ArticlePharmacoEconomics2018
Price Transparency for Whom? In Search of Out-of-Pocket Cost Estimates to Facilitate Cost Communication in Cancer Care.
Article in PharmacoEconomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Price transparency in Iranian healthcare market.Health policy OPEN · 2024Review
- Career disruption and limitation of financial earnings due to cancer.JNCI cancer spectrum · 2023Article
- Financial burden among cancer patients: A national-level perspective.Cancer medicine · 2023Article
- Cancer-Related Care Costs and Employment Disruption: Recommendations to Reduce Patient Economic Burden as Part of Cancer Care Delivery.Journal of the National Cancer Institute. Monographs · 2022Article
- BITES study: A qualitative analysis among emergency medicine physicians on snake envenomation management practices.PloS one · 2022Article
- Communication research at the National Cancer Institute, 2013-2019: a grant portfolio analysis.Cancer causes & control : CCC · 2021Article
- Financial Hardship in Survivorship Care Delivery.Journal of the National Cancer Institute. Monographs · 2021Article
- Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market.JNCI cancer spectrum · 2021Article
- Delivery of Financial Navigation Services Within National Cancer Institute-Designated Cancer Centers.JNCI cancer spectrum · 2021Article
- Protocol for studying the efficiency of ChemoCalc software in helping patients to understand drug treatment costs for breast cancer: A multicenter, open-label, randomized phase 2 study.Contemporary clinical trials communications · 2021Article
- Where advocacy meets patient-centered care-cost considerations in breast reconstruction decision-making.Gland surgery · 2021Review
- Out-of-Pocket Cancer Care Costs and Value Frameworks: A Case Study in a Community Oncology Practice with a Financial Navigator Program.PharmacoEconomics - open · 2020Article
- Understanding Financial Hardship Among Cancer Survivors in the United States: Strategies for Prevention and Mitigation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Review
- Perspectives on the Costs of Cancer Care: A Survey of the American Society of Breast Surgeons.Annals of surgical oncology · 2019Article
- Financial burden amongst cancer patients treated with curative intent surgery alone.American journal of surgery · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.